PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced the expansion of its "No Wash" ALPHA (Amplified Luminescent Proximity Homogeneous Assay) Technology portfolio. The Company is introducing 28 new highly sensitive cell signaling pathway and biomarker research assay kits, that provide researchers with rich data to help advance the study of diseases including cancer, inflammatory and neurodegenerative disorders.
“Working closely with innovators in life sciences, PerkinElmer is proud to continue its leadership and commitment to customers by remaining the only provider of complete ALPHA Technology assay solutions, which are fully validated on the Company's instrumentation to ensure optimal performance.”
The 28 new offerings include 9 AlphaScreen® SureFire® and 19 AlphaLISA® "No-Wash" immunoassay kits, bringing the combined number of ALPHA-based kits to 174 assays.
"As scientific demand increases for sophisticated and robust methods for measuring cell signaling pathways and biomarkers for use in disease research, PerkinElmer remains at the forefront in meeting these critical needs," said Richard Eglen, PhD, president, Bio-discovery, PerkinElmer. "Working closely with innovators in life sciences, PerkinElmer is proud to continue its leadership and commitment to customers by remaining the only provider of complete ALPHA Technology assay solutions, which are fully validated on the Company's instrumentation to ensure optimal performance."
PerkinElmer's AlphaScreen® SureFire® endogenous cellular kinase assays enable researchers to better understand the expression and function of particular phospho-proteins within cellular pathways. By offering scientists a simple method of obtaining highly specific and discrete results for their protein of interest, these extremely sensitive new kits provide increased insight for researchers to understand cell signaling in primary cells and endogenous systems.
The Company's AlphaLISA® "No-Wash" immunoassay kits enable the study of biomarkers for multiple diseases by offering more options for human and mouse proteins. In addition, the kits simplify complex protocols and increase the ability to automate high-throughput processes.
PerkinElmer is the exclusive provider of ALPHA-based assays, which have been fully validated on the Company's instrumentation. ALPHA technology is a powerful, proprietary bead-based platform allowing highly sensitive detection of biomolecules and biomolecular interactions, while removing unwieldy wash steps and eliminating labor intensive processes that are difficult to automate. It allows researchers to overcome traditional limitations associated with ELISA and Western Blotting, yielding precious savings in time, samples and antibody usage.
PerkinElmer expands genomic testing services with ultrarapid whole genome sequencing